Published in final edited form as:

Biochemistry. 2010 June 15; 49(23): 4841–4851. doi:10.1021/bi100119t.

Dihydropyrimidinone Positive Modulation of Delta Subunit-containing GABA_A Receptors, Including an Epilepsy-linked Mutant Variant

Ryan W. Lewis[‡], John Mabry^{||}, Jason G. Polisar^{||}, Kyle P. Eagen^{‡,⊥}, Bruce Ganem^{||}, and George P. Hess^{‡,*}

[‡]Department of Molecular Biology and Genetics, Biotechnology Building, Cornell University, Ithaca, New York 14853-2703

^{||}Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853-1301

Abstract

γ -Aminobutyric acid receptors (GABA_A receptors) are ligand-gated chloride channels that play a central role in signal transmission within the mammalian central nervous system. Compounds that modulate specific GABA_A receptor subtypes containing the δ subunit are scarce, but could be valuable research tools and starting points for potential therapeutic agents. Here we report a class of dihydropyrimidinone (DHPM) heterocycles that preferentially potentiate peak currents of recombinant GABA_A receptor subtypes expressed in HEK293T cells containing the δ subunit. Using the three-component Biginelli reaction, thirteen DHPMs with structural features similar to those of the barbiturate phenobarbital were synthesized; one DHPM used (monastrol) is commercially available. Up to a ~3-fold increase in the current from recombinant $\alpha_1\beta_2\delta$ receptors was observed with the DHPM compounds JM-II-43A or monastrol when coapplied with saturating GABA concentrations, similar to the current potentiation observed with the nonselective potentiating compounds phenobarbital and tracazolate. No agonist activity was observed for the DHPMs at the concentrations tested. A kinetic model was used in conjunction with dose-dependent measurements to calculate apparent dissociation constant values for JM-II-43A (400 μ M) and monastrol (200 μ M) at saturating GABA concentrations. Recombinant receptors composed of combinations of α_1 , α_4 , α_5 , α_6 , β_2 , β_3 , γ_{2L} , and δ subunits were examined with JM-II-43A to demonstrate the preference for potentiation of δ -subunit-containing receptors. Lastly, reduced currents from receptors containing the mutated (E177A) subunit, described by Dibbens et al. (2004) as a heritable susceptibility allele for generalized epilepsy with febrile seizures plus, are also potentiated by these DHPMs.

Graphical Abstract

*To whom correspondence should be addressed. gph2@cornell.edu Telephone: (607) 255-4809. Fax: (607) 255-6249.

[⊥]Current address: Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305-5126

The neurotransmitter γ -aminobutyric acid (GABA)¹ activates a class of ligand-gated chloride ion channels known as GABA_A receptors that are important for regulation of neurotransmission in the central nervous system (CNS) (1). Heteropentameric combinations of nineteen different GABA_A receptor subunits (α_{1-6} , β_{1-3} , γ_{1-3} , δ , ϵ , θ , π , and ρ_{1-3}) (2) determine the localization, pharmacology, biophysical properties, and cellular roles of these receptors (3–6). In contrast to GABA_A receptor subtypes that are localized in synapses and have a phasic role in signal transmission, receptors containing the δ subunit and located peri- and/or extra-synaptically are thought to have an important role in regulating neurotransmission through tonic inhibition (5, 7, 8). The importance of the δ subunit for neuronal signaling is exemplified in knockout mice lacking the δ subunit that are more susceptible to seizures and exhibit attenuated responses to neurosteroids compared to normal mice (9, 10). In addition, point mutations within several different GABA_A receptor subunits have been genetically associated with various forms of epilepsy and seizures (11), such as point mutations E177A (glutamate to alanine), R220H (arginine to histidine), or R220M (arginine to methionine) in the δ subunit that are genetically linked to general epilepsy with febrile seizures plus and juvenile myoclonic epilepsy (12, 13). How these individual mutations within the δ subunit affect the function of GABA_A receptors is not fully understood, but single-channel studies of the $\alpha_1\beta_2\delta$ receptor indicate that the E177A and R220H mutations alter the equilibrium between the open- and closed-channel states of the receptor (14).

Changes in the mechanism of the $\alpha_1\beta_2\delta$ receptors due to the E177A mutation may reduce the channel-opening equilibrium constant (Φ^{-1}) of the receptor, as was determined (15) for the epilepsy-linked $\gamma_{2L(K289M)}$ mutant subunit reported by Baulac *et al.* in 2001(16). Based on the proposed mechanism of the GABA_A receptor (15) (Figure 3A), we hypothesized and determined (17) that phenobarbital, a barbiturate anticonvulsant, potentiates GABA_A receptors by binding to the open-channel conformation of the receptor with a higher affinity ($K_{app} = 0.23 \pm 0.06$ mM) than to the closed-channel conformation ($K_{app} = 1.08 \pm 0.32$ mM), stabilizing the open-channel state and thus increasing the channel-opening equilibrium constant. While the mutated $\alpha_1\beta_2\gamma_{2L(K289M)}$ receptor, upon activation with saturating concentrations of GABA, exhibits a current only ~ 35 % that of the wild-type receptor (15),

¹Abbreviations: ATCC, American Type Culture Collection; CNS, central nervous system; DHPM, dihydropyrimidinone; DMEM, Dulbecco's Modified Eagle's Medium; DMSO, dimethylsulfoxide; FBS, fetal bovine serum; GABA, γ -aminobutyric acid; GABA_A receptor, γ -aminobutyric acid type A receptor; NMDA, *N*-methyl-D-aspartic acid; THDOC, 3 α ,21-dihydroxy-5 α -pregnan-20-one

in the presence of phenobarbital the current amplitude is increased to ~ 50 % that of the wild-type receptor (17).

In an effort to find compounds that potentiate the current of GABA_A receptors to a greater extent than does phenobarbital, we synthesized several dihydropyrimidinones (DHPMs) with structural characteristics similar to phenobarbital and tested them on the epilepsy-linked $\alpha_1\beta_2\gamma_{2L}(K289M)$ and $\alpha_1\beta_2\delta(E177A)$ receptors as well as their corresponding wild-type $\alpha_1\beta_2\gamma_{2L}$ and $\alpha_1\beta_2\delta$ receptors. Although DHPMs did not potentiate currents of the γ -subunit-containing wild-type $\alpha_1\beta_2\gamma_{2L}$ or mutated $\alpha_1\beta_2\gamma_{2L}(K289M)$ receptors, they did potentiate (~3-fold) the δ -subunit-containing wild-type $\alpha_1\beta_2\delta$ and mutated $\alpha_1\beta_2\delta(E177A)$ receptors. Thus, these DHPMs selectively modulate GABA_A receptor subtypes.

It is known that GABA_A receptors containing the δ subunit are pharmacologically distinguishable from other receptor subtypes by their higher sensitivity to zinc ion inhibition (5, 18), greater sensitivity to (and efficacy of) potentiation by tracazolate (8, 19) and neurosteroids such as 3 α , 21-dihydroxy-5 α -pregnan-20-one (THDOC) (8, 20), and a greater sensitivity to the agonist gaboxadol (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol or THIP) (18, 21, 22). However, most of these molecules also act on other GABA_A receptor subtypes. Barbiturates and many other drugs, which have been used for treating epilepsy, depression, anxiety, insomnia and other diseases (23–26), also indiscriminately affect various GABA_A receptor isoforms (2) including, but not limited to, δ -subunit-containing receptors, and often result in undesirable side effects (26–28). Ketamine (29), ethanol (20, 30, 31) and two benzamides (32) have been previously identified as acting specifically on δ -subunit-containing receptor isoforms. Ketamine is a positive allosteric modulator as well as a partial agonist of $\alpha_6\beta_2\delta$ and $\alpha_6\beta_3\delta$ GABA_A receptors and an inhibitor of *N*-methyl-D-aspartic acid (NMDA) receptors (29). While somewhat controversial (33, 34), ethanol is reported to primarily potentiate δ -subunit-containing receptors at low agonist concentrations that are similar to those the receptors may experience extra-synaptically (30, 31, 35). The two reported benzamide compounds are allosteric modulators of $\alpha_4\beta_3\delta$ GABA_A receptors, with one of the two compounds, DS1, also acting as a partial agonist (32).

The family of dihydropyrimidinones we report here allosterically and selectively potentiate currents of several GABA_A receptor subtypes, with a preference for potentiating receptors containing the δ subunit. Various combinations of the subunits α_1 , α_4 , α_5 , α_6 , β_2 , β_3 , γ_{2L} and δ were transiently expressed in HEK293T cells for a total of twelve subtypes that were electrophysiologically tested with the DHPM JM-II-43A (methyl 6-methyl-2-oxo-4-phenyl-3,4-dihydro-1H-pyrimidine-5-carboxylate). JM-II-43A potentiated currents from δ -subunit-containing receptors and the $\alpha_4\beta_2$ receptor subtype but did not change the average peak currents corrected for receptor desensitization (36) of the other GABA_A receptor subtypes examined. Currents from $\alpha_1\beta_2\delta$ receptors over the full dose-dependent range of GABA concentrations (saturating and sub-saturating) were potentiated anywhere from 2.9- to 4-fold by JM-II-43A similar to, or greater than, other reported GABA_A receptor potentiators such as phenobarbital and tracazolate (8, 17, 19). Thirteen DHPM compounds were generated through use of a single-step multi-component reaction (37) and one, monastrol, was purchased. All fourteen compounds were tested on $\alpha_1\beta_2\delta$ receptors, yielding a range of potentiation activities. No agonist activity was observed for any of the DHPMs

tested. Lastly, these DHPMs potentiated currents of $\alpha_1\beta_2\delta_{(E177A)}$ mutated receptors that have been genetically linked to epilepsy to a similar extent as those of wild-type $\alpha_1\beta_2\delta$ receptors.

MATERIALS AND METHODS

Reagents, Synthesis and Preparation of Dihydropyrimidinones

Monastrol was purchased from Tocris (Ellisville, MO). Other reagents were obtained from Sigma Aldrich, Fisher Scientific, or EM Science. GABA solutions were serially diluted from a frozen stock of 100 mM GABA stored at -20°C and made weekly. DHPMs were synthesized as described previously (37). Monastrol and DHPMs were dissolved in pure anhydrous DMSO before being diluted 1:200 with extracellular buffer at 65°C for a final concentration of either 4 mM or 2 mM compound in 0.5 % DMSO. The 0.5 % DMSO aided in compound solubility, with no observed effect on GABA_A receptor currents. The DHPM solutions were cooled to room temperature and serially diluted with extracellular buffer as needed.

Cell Culture and Transient Transfection

HEK293T cells were obtained from the American Type Culture Collection (ATCC) (Manassas, VA) and cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10 % fetal bovine serum (FBS), 100 units/mL penicillin and 0.1 mg/mL streptomycin. Cells were maintained at 37°C with 5 % CO_2 . cDNAs encoding the α_1 , α_4 , α_5 , α_6 , β_2 , β_3 and γ_{2L} subunits of the rat GABA_A receptor in mammalian pRK-5 expression vectors were kindly provided by Professors H. Lüddens (Johannes Gutenberg - Universität, Mainz, Germany) and P. H. Seeburg (Max-Plank-Institut für medizinische Forschung, Heidelberg, Germany). cDNA encoding the δ subunit of the rat GABA_A receptor in the pExpress-1 vector was obtained from ATCC. The pGreen Lantern plasmid (Life Technologies Inc., Gaithersburg, MD) was used as a cell transfection marker. A total of 4 μg of plasmid DNA was transfected, with the plasmid ratios being 1:1:0.1 for $\alpha:\beta:\text{pGreen}$ Lantern and 1:1:10:0.1 for both $\alpha:\beta:\gamma_{2L}:\text{pGreen}$ Lantern and $\alpha:\beta:\delta:\text{pGreen}$ Lantern. These ratios were used to strongly bias the expression of a subunit of interest (i.e. γ_{2L} or δ) relative to the expression levels of α and β subunits to ensure inclusion of the modulatory subunit in the active receptors. For δ -subunit-containing receptors this was clearly identifiable by the characteristic lack of, or limited degree of, receptor desensitization. Currents measured from cells presumed to be expressing $\alpha\beta$ receptors that showed greater degrees of desensitization were very infrequent; but if observed the cell was discarded and data was not used. PolyFect transfection reagent (Qiagen, Valencia, CA) or polyethylenimine (PEI) (Polysciences Inc. Warrington, PA) was used for transient transfection of cells. The Qiagen protocol for transient transfection with PolyFect was followed with the exception that the DMEM/reagent mixture was replaced after 5-7 hours with fresh DMEM/10 % FBS. PEI was used as reported (38) with a PEI:DNA ratio of 4:4 ($\mu\text{g}:\mu\text{g}$) and replacement of medium with fresh DMEM/10 % FBS after 4-7 hours. When PEI was used the HEK293T cells had greater transfection efficiencies and were healthier; no differences in receptor function were observed.

Molecular Biology

Mutations were introduced to the δ subunit by the QuikChange site-directed mutagenesis technique (Stratagene, La Jolla, CA) and verified by DNA sequencing. The E177A mutation of the δ subunit was introduced through polymerase chain reaction amplification with the primer 5'-GGA CAG GCA GGC GTG CAT GCT GGA CCT GGA GAG C-3' and the reverse complement (Integrated DNA Technologies, Coralville, IA).

Whole-cell Current Recordings

Cells were bathed in an extracellular buffer composed of 145 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 1.5 mM MgCl_2 , and 10 mM HEPES (4-2-hydroxyethyl)-1-piperazineethanesulfonic acid) brought to pH 7.4 with 5 N NaOH. Individual cells in a whole-cell configuration were lifted from the dish with a borosilicate glass pipette and suction. Borosilicate glass pipettes were made from capillaries with a 1.5 / 1.12 mm outer / inner diameter (World Precision Instruments Inc., Sarasota, FL) and heat-polished on a microforge to yield pipettes with open-end resistances of 3.0–5.0 M Ω . Pipettes were filled with an intracellular solution composed of 140 mM CsCl, 10 mM tetraethylammonium chloride, 10 mM EGTA (ethylene glycol bis (β -aminoethyl ether)-*N, N, N', N'* tetraacetic acid), 2 mM MgCl_2 , and 10 mM HEPES brought to pH 7.4 with 5 N CsOH. All measurements were carried out with a constant membrane potential of –60 mV, at ambient temperature (~22 °C). An Axopatch 200B amplifier, Digidata 1322A digitizer and Clampex 9.0 software (Molecular Devices, Sunnyvale, CA) were used for recording whole-cell currents, as previously described by Hamill *et al.* (39). Data was filtered with the Axopatch 200B internal Bessel filter at 2 kHz with a digital sampling frequency of 20 kHz.

Rapid Solution Application

Rapid applications of ligands to cells expressing the receptor of interest were performed with the cell-flow technique as previously described by Udgaonkar *et al.* (36). Briefly, a cell in the whole-cell current-recording mode in extracellular buffer was suspended from the recording electrode ~200 μm in front of the porthole of a stainless steel U-tube. Solution was actively pumped with a peristaltic pump into one end of the U-tube at a typical rate of ~1.5 cm/s and drawn from the other end of the U-tube with the peristaltic pump at a greater rate. This causes extracellular buffer in the dish to be drawn through the porthole of the U-tube, preventing the leakage of solutions in the U-tube on to the cell. The flow of solution out of the porthole is regulated by a solenoid Lee Control Valve (Lee Co., Essex, CT) directed by Clampex software. After an application period, the solution from the dish is again drawn into the porthole of the U-tube, rapidly removing the recently applied solution. Solution applications were spaced a minimum of 2 – 2.5 minutes apart, permitting receptors time to recover from desensitized states.

Current Measurement Analysis and Correction

Many neurotransmitter receptors undergo rapid desensitization, which can have a significant effect on the observed peak current amplitudes but can be corrected for as previously described (36). The observed peak amplitudes of non- δ -subunit-containing GABA_A receptor currents, in the absence or presence of modulators, were corrected for desensitization by

fitting the desensitization phase of each current trace with a three-component exponential function. The time constants obtained from the fit were used for (i) comparing how compounds alter the rate of receptor desensitization and (ii) estimating the true current amplitudes by accounting for receptor desensitization (36, 40) that occurs during the rising phase of the receptor current trace (41). Measured currents from GABA_A receptors containing a δ subunit characteristically display limited (if any) desensitization (42) and, therefore, were not corrected. To normalize current amplitudes between cells all receptor currents from a single cell were divided by the current amplitude evoked by a control measurement of current induced by saturating 1 mM GABA ($I_A / I_{Control}$). Dose-dependent data were plotted with their relative standard errors and fitted with either equation [1] or equation [2] using non-linear least squares regression conducted with Origin V. 3.5 data analysis software (OriginLab Corp., Northampton, MA). All reported values of dissociation constants estimated by non-linear least squares fitting are reported with relative standard errors.

RESULTS

Most GABA_A receptor subtypes are modulated by a variety of small molecules, including barbiturates such as phenobarbital and benzodiazepines such as diazepam, both of which are anticonvulsants that act by positively modulating (potentiating) currents of GABA_A receptors (3). Many different molecules have been reported to potentiate GABA_A receptors (several examples are shown in Figure 1A). With their structural resemblance to phenobarbital and pentobarbital, DHPMs JM-II-43A (methyl 6-methyl-2-oxo-4-phenyl-3,4-dihydro-1H-pyrimidine-5-carboxylate) and monastrol were considered likely to potentiate GABA_A receptors (Figure 1A).

JM-II-43A and the other derivatives (except for monastrol, which is commercially available), shown in Figure 1B, were synthesized using a multi-component Biginelli reaction as previously described (37). The DHPMs synthesized were first tested for their solubility at a concentration of 1 to 4 mM in aqueous extracellular buffer with 0.5 % dimethyl sulfoxide (DMSO); most were soluble at concentrations up to 2 mM. To determine whether the DHPM compounds listed (Figure 1B) potentiate recombinant GABA_A receptors, the cell-flow technique (36) was used to rapidly co-apply 1 mM JM-II-43A and 1 mM GABA to various receptor subtypes transiently expressed in HEK293T cells. Representative current traces evoked by 1 mM GABA alone or co-applied with 1 mM JM-II-43A are shown for $\alpha_1\beta_2$, $\alpha_1\beta_2\gamma_{2L}$, and $\alpha_1\beta_2\delta$ receptor subtypes (Figure 2A). Currents of specific receptor subtypes, such as $\alpha_1\beta_2\delta$, were potentiated, whereas slight increases in the rates of desensitization were observed with currents of $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2L}$ receptor subtypes (Figure 2A). When co-applied with 1 mM JM-II-43A and 1 mM GABA receptor subtypes $\alpha_1\beta_2\delta$, $\alpha_1\beta_3\delta$, $\alpha_4\beta_2$, $\alpha_4\beta_2\delta$, $\alpha_5\beta_2\delta$ and $\alpha_6\beta_3\delta$ also demonstrated potentiation anywhere from 1.3- to 3.4-fold the current evoked by 1 mM GABA alone. No changes in corrected peak current amplitudes were observed for currents of receptor subtypes $\alpha_1\beta_2$, $\alpha_1\beta_2\gamma_{2L}$, $\alpha_1\beta_3$, $\alpha_4\beta_2$, $\alpha_5\beta_2$, $\alpha_5\beta_3$ and $\alpha_6\beta_3\gamma_{2L}$. However, it was noted that several of these receptor subtypes had small changes in the rates of desensitization. For unknown reasons, limited expression of receptor subtypes $\alpha_5\beta_3\delta$, $\alpha_6\beta_2$, and $\alpha_6\beta_3$ was observed when transiently transfected in HEK293T cells, preventing the examination of the effect of JM-II-43A on these receptor

subtypes. The observed low expression of the $\alpha_6\beta_2$ receptor subtype agrees with a previous report in which *Xenopus laevis* oocytes were used as an expression system (43). However $\alpha_6\beta_3$ receptors have been successfully expressed in *X. laevis* oocytes (31) and it is not known why expression of these receptors is limited in HEK293T cells. The potentiation mechanism of GABA_A receptors by JM-II-43A was further investigated with the $\alpha_1\beta_2\delta$ receptor subtype because of the high degree of potentiation and satisfactory expression level of the subtype in HEK293T cells. With the $\alpha_1\beta_2\delta$ subtype the mean current measured in the presence of 1 mM JM-II-43A plus 1 mM GABA was 2.9-fold larger than in the presence of 1 mM GABA alone (Figure 2A-C). The maximum (3.5-fold) potentiation of current occurred with 1.5 mM JM-II-43A. In the presence of 3 μ M GABA currents observed for the $\alpha_1\beta_2\delta$ receptor subtype are only 25 % of the maximal current response (EC_{25}), indicating that the receptors are primarily in a closed-channel state. However, upon co-application of 3 μ M GABA and 1 mM JM-II-43A, receptor currents are potentiated up to ~ 4-fold compared to those evoked by 3 μ M GABA alone (Figure 2C). To better describe how JM-II-43A affects the receptors, dose-dependent data (Figure 2C) was fitted with equation [1] to obtain values for the apparent dissociation constant of JM-II-43A ($*K_{d(JM-II-43A)}$).

JM-II-43A may potentiate currents of $\alpha_1\beta_2\delta$ receptors by preferentially binding to the open-channel form of the receptor, thus shifting the receptor channel-opening equilibrium toward the open-channel state. This mechanism would be similar to that described for the potentiation of the $\alpha_1\beta_2\gamma_{2L(K289M)}$ receptor by phenobarbital (Figure 3) (3, 17). It would require that JM-II-43A binds with higher affinity to the open-channel state than to the closed-channel state of the receptor. Therefore, the dissociation constant of JM-II-43A was determined in the presence of 1 mM and 3 μ M GABA to assess the compound's binding affinity for the $\alpha_1\beta_2\delta$ receptor in the open- and closed-channel states, respectively (Figure 2C). Various concentrations of JM-II-43A were co-applied with either 1 mM or 3 μ M GABA, and equation [1] (44) was used to evaluate the JM-II-43A dissociation constant, K_d .

$$\frac{I_p}{I_o} = I_o + (R_{MAX})(1 + (K_d/[Cpd])^h)^{-1} \quad [1]$$

Equation [1], which has been used previously to measure barbiturate interactions with GABA_A receptors (17, 44), relates the ratio of measured current amplitudes (I_p/I_o) induced by a constant GABA concentration in the presence (I_p) or absence (I_o) of the compound of interest ($[Cpd]$), JM-II-43A. R_{MAX} is the maximum I_p/I_o ratio observed when the potentiating compound is co-applied with GABA. The empirical parameter h is equivalent to the Hill coefficient. Because 1 mM JM-II-43A does not saturate $\alpha_1\beta_2\delta$ receptors at either 1 mM or 3 μ M GABA, and is not easily soluble at higher concentrations, fitting the dose-dependent data in Figure 2C afforded only the apparent value of its dissociation constant ($*K_{d(JM-II-43A)}$) (The $*K_d$ is approximately equal to the EC_{50}). For the $\alpha_1\beta_2\delta$ receptor the values of $*K_{d(JM-II-43A)}$ were estimated to be $410 \pm 74 \mu$ M and $810 \pm 32 \mu$ M in the presence of 1 mM and 3 μ M GABA, respectively. (The measured constants for various receptors and conditions can be found in Table 1.) Hill coefficients of 2.1 and 2.2 were obtained for these two fittings, values similar to 2.2 (45), 1.5 (44), and 1.5–1.9 (17) previously observed for phenobarbital modulation of GABA_A receptors.

The apparent dissociation constants of these compounds are relatively large, so it was of interest to investigate if these compounds rapidly or slowly associate with the receptors. To address this question we designed an experiment similar to that described by Wallner et al. (31), in which whole-cell currents were recorded upon application of the modulating compound at various concentrations while the receptors are continually in the presence of 2 μ M GABA. A perfusion system was used to exchange the buffer bathing the cell with buffer containing 2 μ M GABA (EC₁₅), followed by increasing concentrations of JM-II-43A co-applied with 2 μ M GABA using a U-tube. Not only does this data (Figure 2D) clearly display the dose-dependent effect of JM-II-43A on the receptor, but the rapid change in the current amplitude upon application demonstrates that JM-II-43A is associating and dissociating with the receptor on a relatively fast time scale. In the current trace the 10% to 90 % response times for the 1 mM and 2 mM JM-II-43A applications were 155 ms and 123 ms, respectively.

Monastrol and other DHPMs also potentiated $\alpha_1\beta_2\delta$ receptors, as shown in Figure 1B. Because monastrol had one of the largest potentiating efficacies at 1 mM in the presence of 1 mM GABA, a full dose-dependent response for this compound was measured (Figure 2E). Fitting of the dose-dependent curve for monastrol yielded a value for the apparent dissociation constant ($*K_{d(\text{monastrol})}$) of $190 \pm 28 \mu\text{M}$, indicating that $\alpha_1\beta_2\delta$ receptors have a higher binding affinity for monastrol than they do for JM-II-43A ($*K_{d(\text{JM-II-43A})} = 410 \pm 74 \mu\text{M}$). Potentiation of the $\alpha_1\beta_2\delta$ receptor currents by monastrol declined above 1 mM, which may be due to solubility limitations of monastrol and/or inhibitory activity at higher concentrations. It is interesting to note that while JM-II-43A had no observed effect on receptor desensitization, monastrol dramatically increases the desensitization rate of $\alpha_1\beta_2\delta$ receptors and causes a large rebound current at the end of ligand application (inset, Figure 2E).

No agonist activity on $\alpha_1\beta_2\delta$ receptors in the absence of GABA was observed for any of the DHPMs tested. However, it is possible that JM-II-43A and the other DHPMs tested potentiate $\alpha_1\beta_2\delta$ receptor currents by changing the receptor affinity for GABA or by acting in cooperation with GABA as an agonist or partial agonist. To test these possibilities, we examined the dose-dependence of GABA on receptor currents in the presence and absence of JM-II-43A (Figure 2F). If the mechanism for $\alpha_1\beta_2\delta$ receptors is similar to that proposed for the $\alpha_1\beta_2\gamma_{2L}$ receptor (Figure 3A), it is possible to estimate the GABA dissociation constant ($K_{I(\text{GABA})}$) by fitting the data with equation [2] (36).

$$I_A = I_M R_M L^2 (L^2 + \Phi(L + K_1)^2)^{-1} \quad [2]$$

This equation describes the expected current amplitude (I_A) evoked by a known agonist concentration (L). I_M represents the current from one mole of receptors in the open-channel state and R_M the number of moles of receptors on the cell surface. Experimentally, we used the current amplitude at a saturating concentration of the activating ligand (GABA) as the $I_M R_M$ value and the observed current amplitude as I_A . Φ is the channel-closing equilibrium constant (the reciprocal of the channel-opening equilibrium constant), defined in Figure 3A. Fitting the GABA dose-dependent response data from $\alpha_1\beta_2\delta$ receptors with equation [2]

gave values for K_I (GABA) of $9.9 \pm 1.1 \mu\text{M}$ and $7.0 \pm 1.5 \mu\text{M}$ in the absence and presence of 1 mM JM-II-43A, respectively. These values agree well with the previously reported dose-dependent curve of the $\alpha_1\beta_2\delta$ receptor subtype (8). Compounds were also tested, up to concentrations of 4 mM, in the absence of GABA and no induced currents were observed. Data for JM-II-43A in the absence of GABA is shown in Figure 2C.

GABA_A receptors containing the δ subunit typically exhibit limited desensitization and $\alpha_1\beta_2\delta$ receptor desensitization was not altered by JM-II-43A. However, JM-II-43A did alter the desensitization phase of current recorded from $\alpha_1\beta_2$ (Figure 2A), $\alpha_1\beta_2\gamma_{2L}$ (Figure 2A), $\alpha_1\beta_3$, $\alpha_4\beta_2$, $\alpha_5\beta_2$, $\alpha_5\beta_3$ and $\alpha_6\beta_3\gamma_{2L}$ receptor subtypes. The rate at which ligand-gated ion channels, such as GABA_A receptors $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2L}$, pass into a desensitized state and how modulating compounds change the rate of desensitization can be described by time constants (τ_x). The values of the time constants were obtained from fitting the desensitization phase of each current trace with an exponential function (46), shown below:

$$I = A_1(e^{t/\tau_1}) + A_2(e^{t/\tau_2}) + A_3(e^{t/\tau_3}) + C \quad [3]$$

Equation [3] describes the desensitization of current traces where t is time, A_x represents the relative amplitude of component x and C the current remaining at the end of the GABA application period. In previous studies, ligand-gated ion channels currents are typically fitted with a two-component exponential function to describe the fast and slow desensitization rates observed (40, 46), but in the presence of DHPMs a third component was needed for appropriate fitting. Therefore, all traces analyzed for desensitization were fitted with a three-component exponential function so that comparisons could be made between the presence and absence of modulating compounds. The values obtained for τ_x were also used to determine desensitization-corrected amplitudes of peak currents, as previously described (36). JM-II-43A changed the desensitization rate of both $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2L}$ receptors but did not affect the desensitization-corrected current amplitudes (Figure 2A, Table 2). In Table 2 the resulting time constants and relative amplitudes are listed for $\alpha_1\beta_2$ receptors (9 independent cells) and $\alpha_1\beta_2\gamma_{2L}$ receptors (12 independent cells) when 1 mM GABA or 1 mM JM-II-43A with 1 mM GABA was applied to them.

Since JM-II-43A and monastrol potentiated the $\alpha_1\beta_2\delta$ subtype, these compounds were also tested on receptors that contained the single amino-acid mutation E177A within the δ subunit. GABA_A receptors $\alpha_1\beta_2\delta_{(E177A)}$ [as well as $\alpha_4\beta_2\delta_{(E177A)}$] are reported to have significantly reduced currents (12, 14) due to changes in their kinetic properties, decreasing the channel mean open-time of the receptor as measured in single-channel recordings (14). The extent of the decrease in whole-cell currents for these mutations varied. The reported amplitudes of averaged whole-cell currents from receptors containing the $\delta_{(E177A)}$ subunit range from $\sim 12\%$ ($\alpha_1\beta_2\delta_{(E177A)}$) (12) and $\sim 33\%$ ($\alpha_4\beta_2\delta_{(E177A)}$) (14) to $\sim 66\%$ ($\alpha_1\beta_2\delta_{(E177A)}$) (Figure 4A) of that of the maximum wild-type currents measured at the same concentrations of GABA. The degree of current reduction due to the mutations varied when maximum currents recorded from independent cells were measured, because whole-cell currents depend on the number of moles of receptors on the cell surface, R_M , (Equation [2]), and on transfection efficiencies for each cell. As a result, a large standard error was observed

in the averaged maximum current amplitudes evoked by 1 mM GABA from 34 cells expressing $\alpha_1\beta_2\delta$ receptors and 19 cells expressing $\alpha_1\beta_2\delta_{(E177A)}$ receptors (Figure 4A), but the difference was statistically significant ($p < 0.003$). The dose-response curve of $\alpha_1\beta_2\delta_{(E177A)}$ receptors for JM-II-43A with 1 mM GABA afforded a value of 0.624 ± 0.116 mM for $*K_d(\text{JM-II-43A})$ with a Hill coefficient of 1.7 ± 0.3 (Figure 4B). The value of $*K_d(\text{JM-II-43A})$ at low (3 μM) concentrations of GABA changed to 1.14 ± 0.39 mM with a Hill coefficient of 1.5 ± 0.3 . Very little change in the affinity of $\alpha_1\beta_2\delta_{(E177A)}$ receptors for GABA was observed in the absence ($K_I = 5.68 \pm 0.26$ μM) or presence ($K_I = 8.64 \pm 1.98$ μM) of 1 mM JM-II-43A (Figure 4C). Both 1 mM JM-II-43A and 1 mM monastrol potentiated currents from receptors containing the mutant $\delta_{(E177A)}$ subunit, by 3.2-fold and 2.0-fold respectively (Figure 4D). These values were directly compared to the approximate ~3-fold potentiation of wild-type $\alpha_1\beta_2\delta$ GABA_A receptors by 1 mM JM-II-43A or monastrol in the presence of 1 mM GABA, as well as to potentiation by 1 mM phenobarbital and 10 μM tracazolate (Figure 4D).

DISCUSSION

Many neurological pathologies, including schizophrenia, depression, anxiety, insomnia and epilepsy, are linked to GABA_A receptor dysregulation of signal transmission in the mammalian CNS (25). Understanding how GABA_A receptors work in the CNS, what molecules modulate these receptors, and how various compounds affect their functions is critical information to aid in the treatment of diseases, such as epilepsy, which affects ~ 50 million people world wide (47). Compounds that target subsets or specific GABA_A receptor isoforms allow for more detailed and precise studies and potentially more specific treatment of GABA_A receptor-related disorders. However, the repertoire of known compounds that selectively potentiate currents from GABA_A receptor isoforms containing the δ subunit was limited to ketamine (29), two benzamide molecules (32), and ethanol (30, 31). Here we have established that a family of dihydropyrimidinones also has this selective property. Ketamine, a well characterized allosteric inhibitor of NMDA receptors, was recently reported (29) to selectively potentiate currents of recombinant $\alpha_6\beta_2\delta$ and $\alpha_6\beta_3\delta$ receptors that were expressed in *X. laevis* oocytes. The degree of potentiation reported for ketamine was largest when it was tested with GABA concentrations that evoke 1 % of maximal current (EC_1) and declined with increasing GABA concentrations. The two benzamide molecules described (32) potentiated currents evoked by low (EC_{20}) GABA concentrations when applied to recombinant $\alpha_4\beta_3\delta$ receptors expressed in cells from an $L(tk^-)$ cell line. The effects of the benzamides when co-applied with higher concentrations of GABA were not reported. Potentiation of δ -subunit-containing receptors by ethanol has been reported at both low and high agonist concentrations (30, 31). However, this observed response seems to be a complicated relationship and necessitates further investigation (33, 34).

The structural similarity of DHPMs to the barbiturates pentobarbital and phenobarbital led us to hypothesize that these molecules may similarly potentiate GABA_A receptor currents, but the DHPMs presented in our study have several novel characteristics. These compounds contrast to other compounds such as ketamine and benzamides, which were reported to specifically potentiate one or two receptor subtypes selectively, whereas DHPMs are somewhat selective for potentiation of a subgroup of receptors containing the δ subunit, with

$\alpha_4\beta_2$ receptors being the exception. In addition, the potentiation of GABA_A receptor currents by DHPMs occurs over the entire effective range of GABA concentrations, without the DHPMs alone showing any agonist activity at concentrations up to 4 mM (Figure 2C). It is possible that these DHPMs may act as agonists at higher concentrations than those tested, however their solubility prevented examination of this possibility. This finding also contrasts with barbiturates, such as pentobarbital and phenobarbital, which modulate most GABA_A receptor subtypes and display partial agonist activity at higher concentrations (44, 48). The observation that DHPMs do not change the affinity of the $\alpha_1\beta_2\delta$ receptor for GABA suggest that DHPMs interact with GABA_A receptors at an allosteric binding site; however, it is not known if the binding site is novel or the same one to which barbiturates bind. The binding site for DHPMs is evidently not specific to the presence of the δ subunit as $\alpha_4\beta_2$ receptors were potentiated by DHPMs and these compounds increase desensitization rates of receptor subtypes lacking the δ subunit. These results, and observations previously reported (49) for the potentiation of both $\alpha_4\beta_3$ and $\alpha_4\beta_3\delta$ receptor subtypes by etomidate, propofol and the neurosteroid THDOC, indicate that the delta subunit is not essential for binding and potentiation, but likely assists in facilitating potentiation of several receptor subtypes.

The general mechanism for GABA_A receptors presented here (Figure 3) was originally proposed by Katz and Thesleff for the nicotinic acetylcholine receptor (50), with the later addition of the desensitized states (DL and DL₂) and channel-opening equilibrium constant (Φ^{-1}) (51). This mechanism indicates that observed currents will be affected by any changes in the channel-opening equilibrium caused by receptor mutations or ligands that stabilize either the open-channel or closed-channel receptor state. While the measurement of several kinetic constants, such as k_{open} and k_{closed} , for the specific $\alpha_1\beta_2\delta$ receptor mechanism must await the development of appropriate reagents, results reported here support the hypothesis that potentiation of $\alpha_1\beta_2\delta$ receptors and other receptor subtypes by JM-II-43A may be due to the compound preferentially binding to and stabilizing the open-channel state. JM-II-43A has a higher affinity for the wild-type receptor ($*K_{d(JM-II-43A)} = 410 \pm 74 \mu\text{M}$) at a saturating concentration (1 mM) of GABA (receptor predominantly in the open-channel state) than at a low (3 μM) concentration of GABA (receptor predominantly in the closed-channel state) ($*K_{d(JM-II-43A)} = 810 \pm 32 \mu\text{M}$). It is also possible that DHPMs increase the desensitization rates of $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2L}$ receptor isoforms due to preferential binding to and stabilization of the desensitized receptor state.

Previous chemical kinetic investigations of the $\alpha_1\beta_2\gamma_{2L(K289M)}$ receptor genetically linked to epilepsy (16) used the mechanism proposed in Figure 3A to explain how the mutation decreases the channel-opening equilibrium constant (Φ^{-1}) 5-fold by reducing the channel-opening rate constant (k_{open}) (15). Moreover, the anticonvulsant phenobarbital was found to bind with higher affinity to the open-channel state of the mutated $\alpha_1\beta_2\gamma_{2L(K289M)}$ receptor than to the closed-channel state, shifting the channel-opening equilibrium of the receptor towards the open-channel state (17), reaffirming the receptor mechanism. As with the $\alpha_1\beta_2\gamma_{2L(K289M)}$ isoform, GABA_A receptors containing the mutated $\delta_{(E177A)}$ subunit together with the α_1 and β_2 subunits have reduced current amplitudes in whole-cell current recordings (Figure 4A) (12, 14). The decrease in whole-cell currents of receptors containing the $\delta_{(E177A)}$ subunit is due to a decrease in the mean-open time (τ_{open}) of the receptor (the average period of time that the receptor occupies the state able to conduct current before

closing), as measured in single-channel current recordings (14). The approximate 3-fold increase in current of $\alpha_1\beta_2\delta_{(E177A)}$ receptors when in the presence of 1 mM JM-II-43A is consistent with the compound causing a shift of the channel-opening equilibrium towards the open-channel receptor state. Supporting this hypothesis, the dissociation constant for JM-II-43A for the mutant receptor in the presence of 1 mM GABA (receptor predominantly in the open-channel state) was shifted to a lower value ($K_{d(JM-II-43A)(\delta E177A)} = 624.2 \pm 115.7 \mu\text{M}$) compared to that of the wild type ($K_{d(JM-II-43A)(\delta WT)} = 410 \pm 74 \mu\text{M}$). This observation is expected because the mechanism of the GABA_A receptor indicates that the mutated receptor biases the equilibrium towards the closed-channel state, decreasing the number of receptors in the open-channel state at any one time and thus lowering the affinity of the receptor for JM-II-43A. While these observations do not establish that the E177A mutation or application of JM-II-43A alter the channel-opening equilibrium constant of the receptor, they do support this hypothesis. Once appropriate reagents are developed, it will be of interest to determine if changes in the channel-opening (k_{open}) or channel-closing (k_{closed}) rate constants confirm this hypothesis.

In addition to suggesting that DHPMs potentiate GABA_A receptors by shifting the channel-opening equilibrium to increase receptor currents, our data also supports the increasing amount of literature describing GABA as a partial agonist for δ -subunit-containing GABA_A receptors (8, 20, 31, 49, 52). DHPMs seem to increase the efficacy of GABA to open GABA_A receptors while not changing receptor sensitivity to GABA. As previously suggested (52), the modulation of GABA efficacy on δ -subunit-containing GABA_A receptors may be an important attribute of tonic currents used to regulate neuronal excitation. Taking this one step further, selective modulation of GABA_A receptor subtypes involved with tonic inhibition may yield additional levels of regulation and control. It is interesting to point out that of the receptor subtypes potentiated by DHPMs ($\alpha_1\beta_2\delta$, $\alpha_1\beta_3\delta$, $\alpha_4\beta_2$, $\alpha_4\beta_2\delta$, $\alpha_5\beta_2\delta$ and $\alpha_6\beta_3\delta$), the α_4 - and α_6 -subunit-containing receptors are modulated to a lesser extent than other subtypes, even though α_4 and α_6 are currently thought to be the predominant partnering subunits of the δ subunit in the CNS. These results, in addition to the colocalization of various GABA subunits with the δ subunit in immunocytochemical distributions in the rat brain (53), support the idea that less abundant minor receptor subtypes may still be functionally relevant. In fact, the $\alpha_1\beta_2\delta$ receptor subtype, while not a predominant subtype in much of the CNS, has been reported as a significant subtype in specific hippocampal interneurons (20) and was described as a silent receptor until in the presence of modulators such as the neurosteroid THDOC (20). The increased efficacy of GABA on minor receptor subtypes in the presence of DHPMs and other potentiating compounds suggests that less abundant endogenous receptor subtypes in the nervous system may be selectively modulated to play a significant role in regulating tonic conductance of neurons.

The potentiation efficacy of JM-II-43A and monastrol on $\alpha_1\beta_2\delta$ receptor currents is comparable to that of phenobarbital and tracazolate (Figure 4D). Phenobarbital, which was reported to potentiate $\alpha_1\beta_2\gamma_{2L}$ receptors ~ 1.5-fold (17), has higher efficacy on $\alpha_1\beta_2\delta$ receptors, increasing maximum currents by 2.5-fold. Although tracazolate was reported to potentiate $\alpha_1\beta_2\delta$ currents by ~23-fold when co-applied with 100 μM GABA to *X. laevis* oocytes (8), it increased by only ~ 1.5-fold the whole-cell currents evoked by 1 mM GABA

from $\alpha_1\beta_2\delta$ receptors expressed in HEK293T cells reported here. At saturating GABA concentrations 10 μ M tracazolate was reported to potentiate $\alpha_2\beta_3\delta$ receptors expressed in HEK293 cells by approximately 2.7-fold (54) and $\alpha_1\beta_1\delta$ receptors expressed in *X. laevis* oocytes by 2-fold (19), which both more closely resemble the results reported here for $\alpha_1\beta_2\delta$ receptors. These reported differences in the degree of potentiation by tracazolate support previous suggestions that the expression system may affect the degree of potentiation observed for GABA_A receptor currents (49). However, the direct comparison of potentiation efficacy of JM-II-43A, monastrol, tracazolate and phenobarbital with saturating GABA concentrations in HEK293T cells (Figure 4D) demonstrates that these molecules all increase the efficacy of GABA on $\alpha_1\beta_2\delta$ receptors to a similar extent.

JM-II-43A seems to only increase $\alpha_1\beta_2\delta$ receptor currents without changing the other properties of the observed current. However, the effects of monastrol on $\alpha_1\beta_2\delta$ receptors are clearly more complex as the application of 1 mM monastrol causes not only an increase in the overall current amplitude but also the appearance of both a desensitizing phase in the current response and a large rebound current at the end of the application period (inset, Figure 2E). It is not clear how this compound may be causing these features other than to suggest that the compound stabilizes both a conducting and a non-conducting state. Monastrol was originally identified as a kinesin inhibitor (55) and because of this the activity of monastrol on GABA_A receptors may raise questions as to the specificity of DHPMs and their future as a potential therapeutics. Monastrol itself is a very specific inhibitor of the Eg5 kinesin, with a subsequent report showing that the single change of its sulfur atom to an oxygen atom results in the loss of kinesin inhibition (56). Various DHPMs have biological activity in several other contexts as well, including modulation and inhibition of calcium channels (57). DHPMs that modulate calcium channels were discovered in the process of making derivatives and compounds structurally related to nifedipine and nifedipine-like dihydropyridines (58, 59), compounds that are therapeutically used as vasodilators, antianginals and antihypertensives. In this report JM-II-43A was primarily examined for modulation of specific GABA receptor subtypes. However, we have also tested this DHPM on recombinant GluN1N2A NMDA receptors and recombinant $\alpha_4\beta_2$ nicotinic acetylcholine receptors (nAChRs) separately and transiently expressed in HEK293T cells. It was also tested on endogenous muscle-type nACh receptors of the BC3H1 cell line. At 1 mM concentrations of JM-II-43A coapplied with 10 μ M Glycine/100 μ M Glutamate there was no observed effect of the compound on the NMDA receptor currents. In contrast, both $\alpha_4\beta_2$ and muscle-type nAChRs were inhibited ~ 90% when 1 mM of JM-II-43A was coapplied with 100 μ M carbamylcholine. These results were not entirely unexpected as many barbiturates are known antagonists of nAChRs (60, 61), including pentobarbital (one of the barbiturates this class of DHPMs was modeled after, Figure 1A), which has a reported EC₅₀ of 32 μ M using the endogenous receptors of BC3H1 cells (61). With all this in mind, monastrol and the other DHPMs presented in this report may not be directly relevant for therapeutic use. However, they do display GABA_A receptor subtype specificity that will make them good tools for the study of GABA_A receptors. Furthermore, modifications of these compounds may yield molecules that retain the ability to modulate specific GABA_A receptor subtypes while making the molecules more selective for GABA_A

receptors than the DHPMs examined here. Such molecules would undoubtedly be desirable developments for therapeutic purposes.

Chemical libraries of DHPMs can be readily synthesized through a multi-component Biginelli reaction (37) and can afford access to a wide range of molecules having promising biological applications (57, 62). The accessibility of DHPM derivatives and our present results showing selectivity for potentiation of $\alpha_1\beta_2\delta$ GABA_A receptors, suggest that DHPM derivatives should be useful as biological tools and may be helpful for developing future therapeutic agents to target GABA_A receptor isoforms containing the δ subunit.

Acknowledgments

R.W.L. was supported by the National Institutes of Health Predoctoral Training Grant (5T32GM7273) in Cell and Molecular Biology, and a Teaching Assistantship from the Department of Molecular & Cell Biology, Cornell University. K. P. E. was a Robert and Helen Appel Hunter R. Rawlings III Cornell Presidential Research Scholar and a Cornell Hughes Undergraduate Scholar.

REFERENCES

1. Mehta AK, Ticku MK. An update on GABA_A receptors. *Brain Res Brain Res Rev.* 1999; 29:196–217. [PubMed: 10209232]
2. Sieghart W. Structure, pharmacology, and function of GABA_A receptor subtypes. *Adv Pharmacol.* 2006; 54:231–263. [PubMed: 17175817]
3. Johnston GA. GABA_A receptor pharmacology. *Pharmacol Ther.* 1996; 69:173–198. [PubMed: 8783370]
4. Olsen RW, Sieghart W. GABA_A receptors: Subtypes provide diversity of function and pharmacology. *Neuropharmacology.* 2009; 56:141–148. [PubMed: 18760291]
5. Saxena NC, Macdonald RL. Assembly of GABA_A receptor subunits: role of the delta subunit. *J Neurosci.* 1994; 14:7077–7086. [PubMed: 7525894]
6. Mohler H, Benke D, Benson J, Luscher B, Fritschy JM. GABA_A-receptor subtypes in vivo: Cellular localization, pharmacology and regulation. *Adv Biochem Psychopharmacol.* 1995; 48:41–56. [PubMed: 7653325]
7. Nusser Z, Sieghart W, Somogyi P. Segregation of different GABA_A receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. *J Neurosci.* 1998; 18:1693–1703. [PubMed: 9464994]
8. Zheleznova N, Sedelnikova A, Weiss DS. Alpha1beta2delta, a silent GABA_A receptor: Recruitment by trazolam and neurosteroids. *Br J Pharmacol.* 2008; 153:1062–1071. [PubMed: 18204487]
9. Spigelman I, Li Z, Banerjee PK, Mihalek RM, Homanics GE, Olsen RW. Behavior and physiology of mice lacking the GABA_A-receptor delta subunit. *Epilepsia.* 2002; 43(Suppl 5):3–8. [PubMed: 12121286]
10. Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG, Sage JR, Fanselow MS, Guidotti A, Spigelman I, Li Z, DeLorey TM, Olsen RW, Homanics GE. Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. *Proc Natl Acad Sci U S A.* 1999; 96:12905–12910. [PubMed: 10536021]
11. Macdonald RL, Kang JQ. Molecular pathology of genetic epilepsies associated with GABA(A) receptor subunit mutations. *Epilepsy Curr.* 2009; 9:18–23. [PubMed: 19396344]
12. Dibbens LM, Feng HJ, Richards MC, Harkin LA, Hodgson BL, Scott D, Jenkins M, Petrou S, Sutherland GR, Scheffer IE, Berkovic SF, Macdonald RL, Mulley JC. GABRD encoding a protein for extra- or peri-synaptic GABA_A receptors is a susceptibility locus for generalized epilepsies. *Hum Mol Genet.* 2004; 13:1315–1319. [PubMed: 15115768]
13. Macdonald RL, Gallagher MJ, Feng HJ, Kang J. GABA(A) receptor epilepsy mutations. *Biochem Pharmacol.* 2004; 68:1497–1506. [PubMed: 15451392]

14. Feng HJ, Kang JQ, Song L, Dibbens L, Mulley J, Macdonald RL. Delta subunit susceptibility variants E177A and R220H associated with complex epilepsy alter channel gating and surface expression of alpha4beta2delta GABA_A receptors. *J Neurosci*. 2006; 26:1499–1506. [PubMed: 16452673]
15. Ramakrishnan L, Hess GP. On the mechanism of a mutated and abnormally functioning gamma-aminobutyric acid (A) receptor linked to epilepsy. *Biochemistry*. 2004; 43:7534–7540. [PubMed: 15182195]
16. Baulac S, Huberfeld G, Gourfinkel-An I, Mitropoulou G, Beranger A, Prud'homme JF, Baulac M, Brice A, Bruzzone R, LeGuern E. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: A mutation in the gamma2-subunit gene. *Nat Genet*. 2001; 28:46–48. [PubMed: 11326274]
17. Krivoshein AV, Hess GP. On the mechanism of alleviation by phenobarbital of the malfunction of an epilepsy-linked GABA(A) receptor. *Biochemistry*. 2006; 45:11632–11641. [PubMed: 16981722]
18. Storustovu SI, Ebert B. Pharmacological characterization of agonists at delta-containing GABA_A receptors: Functional selectivity for extrasynaptic receptors is dependent on the absence of gamma2. *J Pharmacol Exp Ther*. 2006; 316:1351–1359. [PubMed: 16272218]
19. Thompson SA, Wingrove PB, Connelly L, Whiting PJ, Wafford KA. Tracazolate reveals a novel type of allosteric interaction with recombinant gamma-aminobutyric acid(A) receptors. *Mol Pharmacol*. 2002; 61:861–869. [PubMed: 11901225]
20. Glykys J, Peng Z, Chandra D, Homanics GE, Houser CR, Mody I. A new naturally occurring GABA(A) receptor subunit partnership with high sensitivity to ethanol. *Nat Neurosci*. 2007; 10:40–48. [PubMed: 17159992]
21. Boehm SL 2nd, Homanics GE, Blednov YA, Harris RA. Delta-subunit containing GABA_A receptor knockout mice are less sensitive to the actions of 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol. *Eur J Pharmacol*. 2006; 541:158–162. [PubMed: 16777089]
22. Wohlfarth KM, Bianchi MT, Macdonald RL. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. *J Neurosci*. 2002; 22:1541–1549. [PubMed: 11880484]
23. Zeller A, Jurd R, Lambert S, Arras M, Drexler B, Grashoff C, Antkowiak B, Rudolph U. Inhibitory ligand-gated ion channels as substrates for general anesthetic actions. *Handb Exp Pharmacol*. 2008;31–51. [PubMed: 18175085]
24. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. *Neurotherapeutics*. 2007; 4:18–61. [PubMed: 17199015]
25. Mohler H. GABA_A receptors in central nervous system disease: anxiety, epilepsy, and insomnia. *J Recept Signal Transduct Res*. 2006; 26:731–740. [PubMed: 17118808]
26. Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. *Expert Opin Investig Drugs*. 2005; 14:601–618.
27. Agid Y, Buzsaki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, Grace A, Lambert JJ, Manji H, Mayberg H, Popoli M, Prochiantz A, Richter-Levin G, Somogyi P, Spedding M, Svenningsson P, Weinberger D. How can drug discovery for psychiatric disorders be improved? *Nat Rev Drug Discov*. 2007; 6:189–201. [PubMed: 17330070]
28. Rudolph U, Mohler H. GABA-based therapeutic approaches: GABA_A receptor subtype functions. *Curr Opin Pharmacol*. 2006; 6:18–23. [PubMed: 16376150]
29. Hevers W, Hadley SH, Luddens H, Amin J. Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits. *J Neurosci*. 2008; 28:5383–5393. [PubMed: 18480294]
30. Sundstrom-Poromaa I, Smith DH, Gong QH, Sabado TN, Li X, Light A, Wiedmann M, Williams K, Smith SS. Hormonally regulated alpha(4)beta(2)delta GABA(A) receptors are a target for alcohol. *Nat Neurosci*. 2002; 5:721–722. [PubMed: 12118257]
31. Wallner M, Hancher HJ, Olsen RW. Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans. *Proc Natl Acad Sci U S A*. 2003; 100:15218–15223. [PubMed: 14625373]

32. Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, Belelli D, Lambert JJ. Novel compounds selectively enhance delta subunit containing GABA_A receptors and increase tonic currents in thalamus. *Neuropharmacology*. 2009; 56:182–189. [PubMed: 18762200]
33. Borghese CM, Harris RA. Studies of ethanol actions on recombinant delta-containing gamma-aminobutyric acid type A receptors yield contradictory results. *Alcohol*. 2007; 41:155–162. [PubMed: 17521845]
34. Kaur KH, Baur R, Sigel E. Unanticipated structural and functional properties of delta-subunit-containing GABA_A receptors. *J Biol Chem*. 2009; 284:7889–7896. [PubMed: 19141615]
35. Mody I, Glykys J, Wei W. A new meaning for "Gin & Tonic": Tonic inhibition as the target for ethanol action in the brain. *Alcohol*. 2007; 41:145–153. [PubMed: 17521846]
36. Udgaonkar JB, Hess GP. Chemical kinetic measurements of a mammalian acetylcholine receptor by a fast-reaction technique. *Proc Natl Acad Sci U S A*. 1987; 84:8758–8762. [PubMed: 2447583]
37. Mabry J, Ganem B. Studies on the Biginelli reaction: A mild and selective route to 3,4-dihydropyrimidin-2(1H)-ones via enamine intermediates. *Tetrahedron Letters*. 2006; 47:55–56.
38. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. *Proc Natl Acad Sci U S A*. 1995; 92:7297–7301. [PubMed: 7638184]
39. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. *Pflugers Arch*. 1981; 391:85–100. [PubMed: 6270629]
40. Hess GP, Udgaonkar JB, Olbricht WL. Chemical kinetic measurements of transmembrane processes using rapid reaction techniques: Acetylcholine receptor. *Annu Rev Biophys Biophys Chem*. 1987; 16:507–534. [PubMed: 2439099]
41. Matsubara N, Hess GP. On the mechanism of a mammalian neuronal type nicotinic acetylcholine receptor investigated by a rapid chemical kinetic technique. Detection and characterization of a short-lived, previously unobserved, main receptor form in PC12 cells. *Biochemistry*. 1992; 31:5477–5487. [PubMed: 1377021]
42. Haas KF, Macdonald RL. GABA_A receptor subunit gamma2 and delta subtypes confer unique kinetic properties on recombinant GABA_A receptor currents in mouse fibroblasts. *J Physiol*. 1999; 514(Pt 1):27–45. [PubMed: 9831714]
43. Hadley SH, Amin J. Rat alpha6beta2delta GABA_A receptors exhibit two distinct and separable agonist affinities. *J Physiol*. 2007; 581:1001–1018. [PubMed: 17395622]
44. Rho JM, Donevan SD, Rogawski MA. Direct activation of GABA_A receptors by barbiturates in cultured rat hippocampal neurons. *J Physiol*. 1996; 497(Pt 2):509–522. [PubMed: 8961191]
45. Neelands TR, Greenfield LJ Jr, Zhang J, Turner RS, Macdonald RL. GABA_A receptor pharmacology and subtype mRNA expression in human neuronal NT2-N cells. *J Neurosci*. 1998; 18:4993–5007. [PubMed: 9634565]
46. Orser BA, McAdam LC, Roder S, MacDonald JF. General anaesthetics and their effects on GABA(A) receptor desensitization. *Toxicol Lett*. 1998; 100–101:217–224.
47. Leonardi M, Ustun TB. The global burden of epilepsy. *Epilepsia*. 2002; 43(Suppl 6):21–25. [PubMed: 12190974]
48. Steinbach JH, Akk G. Modulation of GABA(A) receptor channel gating by pentobarbital. *J Physiol*. 2001; 537:715–733. [PubMed: 11744750]
49. Meera P, Olsen RW, Otis TS, Wallner M. Etomidate, propofol and the neurosteroid THDOC increase the GABA efficacy of recombinant alpha4beta3delta and alpha4beta3 GABA A receptors expressed in HEK cells. *Neuropharmacology*. 2009; 56:155–160. [PubMed: 18778723]
50. Katz B, Thesleff S. A study of the desensitization produced by acetylcholine at the motor end-plate. *J Physiol*. 1957; 138:63–80. [PubMed: 13463799]
51. Cash DJ, Hess GP. Molecular mechanism of acetylcholine receptor-controlled ion translocation across cell membranes. *Proc Natl Acad Sci U S A*. 1980; 77:842–846. [PubMed: 6928684]
52. Bianchi MT, Macdonald RL. Neurosteroids shift partial agonist activation of GABA(A) receptor channels from low- to high-efficacy gating patterns. *J Neurosci*. 2003; 23:10934–10943. [PubMed: 14645489]

53. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. *Neuroscience*. 2000; 101:815–850. [PubMed: 11113332]
54. Yang P, Jones BL, Henderson LP. Role of the alpha subunit in the modulation of GABA(A) receptors by anabolic androgenic steroids. *Neuropharmacology*. 2005; 49:300–316. [PubMed: 15993433]
55. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. *J Cell Biol*. 2000; 150:975–988. [PubMed: 10973989]
56. Maliga Z, Mitchison TJ. Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. *BMC Chem Biol*. 2006; 6:2. [PubMed: 16504166]
57. Kappe CO. Biologically active dihydropyrimidones of the Biginelli-type--a literature survey. *Eur J Med Chem*. 2000; 35:1043–1052. [PubMed: 11248403]
58. Cho H, Ueda M, Shima K, Mizuno A, Hayashimatsu M, Ohnaka Y, Takeuchi Y, Hamaguchi M, Aisaka K, Hidaka T, et al. Dihydropyrimidines: Novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. *J Med Chem*. 1989; 32:2399–2406. [PubMed: 2552119]
59. Atwal KS, Rovnyak GC, Kimball SD, Floyd DM, Moreland S, Swanson BN, Gougoutas JZ, Schwartz J, Smillie KM, Malley MF. Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines. *J Med Chem*. 1990; 33:2629–2635. [PubMed: 2391701]
60. Arias HR, Bhumireddy P, Bouzat C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. *Int J Biochem Cell Biol*. 2006; 38:1254–1276. [PubMed: 16520081]
61. Dilger JP, Boguslavsky R, Barann M, Katz T, Vidal AM. Mechanisms of barbiturate inhibition of acetylcholine receptor channels. *J Gen Physiol*. 1997; 109:401–414. [PubMed: 9089445]
62. Khanetskyy B, Dallinger D, Kappe CO. Combining Biginelli multicomponent and click chemistry: generation of 6-(1,2,3-triazol-1-yl)-dihydropyrimidone libraries. *J Comb Chem*. 2004; 6:884–892. [PubMed: 15530114]

FIGURE 1.

A. Structures of several molecules that potentiate various GABA_A receptor subtypes. Of the many compounds known to modulate GABA_A receptors only ketamine (29), ethanol (20, 30, 31) [though this seems somewhat complicated (33, 34)] and two benzamide compounds (32) have been reported to selectively potentiate δ -subunit-containing receptor subtypes. The structural similarities of JM-II-43A (methyl 6-methyl-2-oxo-4-phenyl-3,4-dihydro-1H-pyrimidine-5-carboxylate), monastrol and other DHPMs (Figure 1B) to pentobarbital and phenobarbital, suggests that DHPMs may also potentiate whole-cell currents from GABA_A receptors. **B.** A one-step Biginelli reaction (37) was used to synthesize derivatives of JM-II-43A. Each compound was tested for solubility and efficacy to potentiate $\alpha_1\beta_2\delta$ GABA_A receptor currents at 1 mM compound and 1 mM GABA. Solubility of each DHPM was determined qualitatively in aqueous extracellular buffer containing 0.5 % DMSO, and is described as soluble (Sol), partially soluble (PSol) or not soluble (NSol). The degree of

current potentiation (fold potentiation) is described as the current induced by 1 mM GABA and 1 mM of the compound divided by the current induced by 1 mM GABA alone ($I_{1 \text{ mM cpd.}} / I_{1 \text{ mM GABA control}}$).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

FIGURE 2.

A. Representative traces showing the effects of 1 mM JM-II-43A on currents evoked by 1 mM GABA with three different receptor isoforms $\alpha_1\beta_2$, $\alpha_1\beta_2\gamma_{2L}$, and $\alpha_1\beta_2\delta$. The current traces for $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2L}$ receptor subtypes were corrected for receptor desensitization (grey line) (36). Current correction for the receptor subtype $\alpha_1\beta_2\delta$ is not needed because limited to no desensitization is observed. **B.** 1 mM GABA with 1 mM JM-II-43A was applied to various receptor subtypes to test the specificity of JM-II-43A current potentiation. Of the subtypes examined here, only the $\alpha_4\beta_2$ receptor subtype and receptors containing the

δ subunit were potentiated by JM-II-43A. Error bars display the standard error, numbers above each bar represent the number of independent cells measured and the asterisk (*) denotes a significant difference ($p < 0.01$), as tested by a one-way ANOVA statistical test. **C.** JM-II-43A dose-dependent curves (0.01 to 2 mM) were obtained from $\alpha_1\beta_2\delta$ receptors for the compound alone (gray squares), in the presence of 1 mM GABA (saturating concentration, black triangles) and in the presence of 3 μ M GABA (effective concentration for 25 % of maximal current response, EC_{25} , open circles). Curves were fitted with equation [1] and gave an apparent dissociation constant for JM-II-43A ($*K_d(\text{JM-II-43A})$) of 410 ± 74 μ M at 1 mM GABA and 810 ± 32 μ M at 3 μ M GABA, with Hill coefficients of 2.1 and 2.2 respectively. The inset shows two representative current traces evoked by 1 mM GABA and 1 mM GABA with 1 mM JM-II-43A. Current amplitudes are normalized to the peak of the 1 mM GABA current response. **D.** A current trace from $\alpha_1\beta_2\delta$ recombinant receptors in a single cell was used to demonstrate the current response upon application of 2 μ M GABA and increasing concentrations of JM-II-43A during the 2 μ M GABA application. 1 mM GABA in the absence of JM-II-43A was applied at the beginning and end of the current trace. This trace displays the dose-dependent modulation of the receptor by JM-II-43A, the increase in amplitude of the current by JM-II-43A, and the rapid association and dissociation of the compound with the receptor during a JM-II-43A application period. **E.** A monastrol dose-dependent curve was obtained with $\alpha_1\beta_2\delta$ receptors in the presence of 1 mM GABA and fitted with equation [1] to calculate an apparent dissociation constant for monastrol ($*K_d(\text{monastrol})$) of 190 ± 28 μ M. Potentiation at concentrations of monastrol above 1 mM decreased, likely due to solubility limitations of the compound and/or possible receptor inhibition. The inset shows two representative current traces evoked by 1 mM GABA and 1 mM GABA with 1 mM monastrol. Current amplitudes are normalized to the peak of the 1 mM GABA current response. **F.** GABA dose-dependent curves obtained with $\alpha_1\beta_2\delta$ receptors in the absence (open symbols) or presence (filled symbols) of 1 mM JM-II-43A were fitted with equation [2] and gave a value for the dissociation constant for GABA (K_d) of 9.9 ± 1.1 μ M and 7.0 ± 1.5 μ M respectively.

All currents were recorded at ambient temperature ($\sim 22^\circ\text{C}$), -60 mV membrane potential and pH 7.4. Measurements from a single cell are normalized by dividing the current amplitude evoked in the presence of an experimental compound by a 1 mM GABA control current measurement (I_A / I_{Control}). The value of each data point shown in C, D and E is the mean of four to fourteen measurements from independent cells and is plotted on a logarithmic scale with error bars representing the standard error.

A

B

FIGURE 3.

A. The mechanism previously proposed for $\alpha_1\beta_2\gamma_{2L}$ GABA_A receptors (15), was originally proposed for the nicotinic acetylcholine receptor by Katz and Thesleff (50), with the addition of the desensitized states (DL and DL₂) and the channel-opening equilibrium constant (Φ^{-1}) proposed later (51). The mechanism describes the receptor (R) binding two ligand molecules (L) with a dissociation constant K_1 . At this stage (RL₂) the receptor is in the closed-channel state, which can change conformation to the open-channel state to allow ion flux across the membrane ($\overline{RL}_2$) and to the subsequent desensitized state (DL₂). DL₂ is a

transiently inactive, closed-channel state of the receptor. The equilibrium between the closed- and open-channel states is described by the channel-opening equilibrium constant (Φ^{-1}). **B.** This mechanism describes the binding of a potentiating compound (P) to $\alpha_1\beta_2\gamma_2\delta$ GABA_A receptors as previously reported (17). The mechanism here was simplified by omitting the desensitization states of the receptor and combining the two steps of ligand binding. The potentiating compound can bind to either the closed- or open-channel state with the relative binding affinities K_P and $\overline{K_P}$, to yield the respective closed- (RL₂P) and open-channel ($\overline{\text{RL}_2\text{P}}$) states of the receptor. The channel-opening and -closing rate constants in the presence of the potentiator are shown as k_{open}^P and k_{closed}^P and define the channel-opening equilibrium constant (Φ^{P-1}) in the presence of a potentiating compound.

FIGURE 4.

Mutated $\alpha_1\beta_2\delta_{(E177A)}$ GABA_A receptors, which give lower average current responses to GABA than do the wild-type receptor (12, 14), were potentiated by JM-II-43A. **A.** Mean current amplitudes evoked by 1 mM GABA from 34 independent cells for wild-type $\alpha_1\beta_2\delta$ and 19 independent cells for mutant $\alpha_1\beta_2\delta_{(E177A)}$ receptors demonstrate a 47% reduction in current amplitude and are shown with relative standard errors. The difference is statistically significant ($p < 0.003$) using a two-tailed t-test assuming unequal variance and an $\alpha = 0.05$. The somewhat large standard errors, despite 34 and 19 independent measurements, are likely

due to large variations in the number of receptors expressed on the surface of each cell. **B.** Fitting equation [1] to the dose-dependent response data from $\alpha_1\beta_2\delta_{(E177A)}$ receptors in the presence of 0.01 to 2 mM JM-II-43A and 1 mM GABA (black triangles), gave a value for the apparent dissociation constant for JM-II-43A ($*K_{d(JM-II-43A)}(E177A)$) of 0.62 ± 12 mM, with a Hill coefficient of 1.7 ± 0.3 . In the presence of 3 μ M GABA (EC_{25}) (open circles) the value for $*K_{d(JM-II-43A)}(E177A)$ was 1.1 ± 0.39 mM, with a Hill coefficient of 1.5 ± 0.3 . **C.** Fitting the GABA dose-dependent data with equation [2] gave values for the dissociation constant (K_I) for GABA from $\alpha_1\beta_2\delta_{(E177A)}$ receptors of 5.68 ± 0.26 μ M (open symbols) and 8.64 ± 1.98 μ M (filled symbols) in the absence and presence of JM-II-43A respectively. Independent measurements from 3–6 cells were made for every concentration shown in B and C and plotted on a logarithmic scale. **D.** Comparison of the potentiation due to saturating concentrations of JM-II-43A, monastrol, phenobarbital or tracazolate coapplied with 1 mM GABA shows that DHPMs positively modulate both $\alpha_1\beta_2\delta$ and $\alpha_1\beta_2\delta_{(E177A)}$ GABA_A receptors to a similar or greater extent than do phenobarbital and tracazolate. The means and relative standard errors shown are calculated from 12 independent cells for JM-II-43A and 3–9 independent cells for monastrol, phenobarbital and tracazolate, normalized to the current response evoked by 1 mM GABA. All current measurements were made at ambient temperature (~ 22 °C), -60 mV membrane potential and pH 7.4.

Apparent dissociation constants obtained for the GABA_A receptor $\alpha_1\beta_2\delta$ subtype and the $\alpha_1\beta_2\delta_{(E177A)}$ variant.

Table 1

Receptor subunit composition	K_I (GABA) (μ M)	K_I (GABA) 1 mM JM-II-43A (μ M)	K_d (JM-II-43A) 1 mM GABA (μ M)	K_d (JM-II-43A) 3 μ M GABA (μ M)	K_d (monomer) 1 mM GABA (μ M)
$\alpha_1\beta_2\delta$	9.9 ± 1.1	7.0 ± 1.5	410 ± 74	810 ± 32	190 ± 28
$\alpha_1\beta_2\delta_{(E177A)}$	5.7 ± 0.26	8.6 ± 2.0	620 ± 120	1140 ± 390	-

Table 2

Parameters obtained from fitting equation [3] to the desensitization phase of $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_{2L}$ GABA_A receptor currents in the presence and absence of JM-II-43A.

Receptor Subunits	Number of cells	Conditions	Mean Corrected Peak Current (pA)	A ₁ (pA)	τ_1 (ms)	A ₂ (pA)	τ_2 (ms)	A ₃ (pA)	τ_3 (ms)	C (pA)
$\alpha_1\beta_2$	9	1 mM GABA	-4680 ± 930	-1480 ± 410	650 ± 150	-1370 ± 270	1270 ± 210	-1150 ± 210	1590 ± 220	760 ± 200
		1 mM GABA + 1 mM JM-II-43A	-5050 ± 990	-2290 ± 450	68 ± 15	-1170 ± 330	600 ± 180	-1190 ± 240	1900 ± 360	590 ± 170
$\alpha_1\beta_2\gamma_{2L}$	12	1 mM GABA	-6210 ± 630	-1490 ± 200	970 ± 270	-1880 ± 310	2090 ± 200	-1710 ± 210	2130 ± 150	1150 ± 160
		1 mM GABA + 1 mM JM-II-43A	-6250 ± 930	-2440 ± 780	460 ± 200	-1500 ± 210	1510 ± 320	-1660 ± 180	2090 ± 240	830 ± 110

Paired current traces from a single cell were obtained by application of 1 mM GABA with and without 1 mM JM-II-43A. The desensitization phase of each current trace was fitted with a three-component exponential equation [3] and using non-linear least-squares regression. The mean values for the parameters are shown above. A_x represents and τ_x represent the current amplitude and time constant associated with the 'x' exponential component. τ_x represents the time constant of the 'x' exponential component, respectively. C is the current amplitude at the end of the fit region.